TickerFacts.

UL Solutions Inc. (ULS): EBITDA

Operating income plus depreciation and amortization for the same annual period and currency, computed by TickerFacts from the filed figures. Not the company's adjusted EBITDA; a year without both inputs is left out.

$710.00M
Year ended 2025-12-31
$752.00M
Trailing 12 months to 2026-06-30
+9.1%
3-year compound annual growth
2022-12-31: $547.00M2023-12-31: $522.00M2024-12-31: $634.00M2025-12-31: $710.00M$710.00M
2022-12-31 EBITDA (USD) 2025-12-31
Period endedEBITDAChange YoYSource filing
2025-12-31$710.00M+12.0%2026-02-19, From 2025-01-01
2024-12-31$634.00M+21.5%2026-02-19, From 2024-01-01
2023-12-31$522.00M-4.6%2026-02-19, From 2023-01-01
2022-12-31$547.00Mn/a2025-02-20, From 2022-01-01

EBITDA at similar companies

Companies with the same SEC industry code (Services-Testing Laboratories), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedEBITDAChange YoY
UL Solutions Inc. (ULS)2025-12-31$710.00M+12.0%
20/20 Biolabs, Inc. (AIDX)2025-12-31-$3.27Mn/m

Compare ULS, AIDX side by side · Screen every company in Services-Testing Laboratories ↗